$RPRX
Royalty Pharma plc Stock $rprx

$rprx Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-K Financial Statement

#000180276821000006 Filed on February 24, 2021

Income Statement

Concept	2019 Q4	2018
Revenue	$457.5M	$1.795B
YoY Change		12.33%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$23.10M	$61.90M
YoY Change		-41.82%
% of Gross Profit
Research & Development	$15.90M	$392.6M
YoY Change		232.99%
% of Gross Profit
Depreciation & Amortization	$5.800M	$33.30M
YoY Change		0.0%
% of Gross Profit
Operating Expenses	-$874.4M	$392.6M
YoY Change		-40.35%
Operating Profit		$1.364B
YoY Change
Interest Expense	$114.5M	$280.0M
YoY Change		-20.56%
% of Operating Profit		20.52%
Other Income/Expense, Net	$100.0K	$153.4M
YoY Change		-9688.06%
Pretax Income	$1.447B	$1.518B
YoY Change		13.0%
Income Tax	$0.00	$0.00
% Of Pretax Income	0.0%	0.0%
Net Earnings	$1.420B	$1.378B
YoY Change		13.86%
Net Earnings / Revenue	310.47%	76.76%
Basic Earnings Per Share
Diluted Earnings Per Share	$2.39	$2.314M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q4	2018	2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$246.2M	$2.386B
YoY Change
Cash & Equivalents	$246.2M	$1.924B	$1.382B
Short-Term Investments	$0.00	$462.0M
Other Short-Term Assets	$92.00K	$24.00M
YoY Change
Inventory
Prepaid Expenses
Receivables		$36.00M
Other Receivables		$163.0M
Total Short-Term Assets	$832.1M	$2.609B
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$124.1M	$8.667B
YoY Change
Other Assets	$45.60M	$19.00M
YoY Change
Total Long-Term Assets	$11.62B	$8.761B
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$832.1M	$2.609B
Total Long-Term Assets	$11.62B	$8.761B
Total Assets	$12.45B	$11.37B
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$4.000M
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due	$282.0M	$281.0M
YoY Change
Total Short-Term Liabilities	$333.4M	$580.0M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt	$5.956B	$6.238B
YoY Change
Other Long-Term Liabilities	$0.00	$0.00
YoY Change
Total Long-Term Liabilities	$5.956B	$6.238B
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$333.4M	$580.0M
Total Long-Term Liabilities	$5.956B	$6.238B
Total Liabilities	$6.308B	$6.882B
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings	$2.825B
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$4.266M
YoY Change
Treasury Stock Shares
Shareholders Equity		$4.488B
YoY Change
Total Liabilities & Shareholders Equity	$12.45B	$11.37B
YoY Change

Cashflow Statement

Concept	2019 Q4	2018
OPERATING ACTIVITIES
Net Income	$1.420B	$1.378B
YoY Change		13.86%
Depreciation, Depletion And Amortization	$5.800M	$33.30M
YoY Change		0.0%
Cash From Operating Activities	$897.4M	$1.618B
YoY Change		14.1%
INVESTING ACTIVITIES
Capital Expenditures	-$489.6M	-$269.6M
YoY Change		-88.23%
Acquisitions
YoY Change
Other Investing Activities	-$151.1M	$573.0M
YoY Change		-18.49%
Cash From Investing Activities	-$640.6M	$303.4M
YoY Change		-119.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change
Debt Paid & Issued, Net		$0.00
YoY Change
Cash From Financing Activities	-566.5M	-$1.379B
YoY Change		1018.49%
NET CHANGE
Cash From Operating Activities	897.4M	$1.618B
Cash From Investing Activities	-640.6M	$303.4M
Cash From Financing Activities	-566.5M	-$1.379B
Net Change In Cash	-309.7M	$542.6M
YoY Change		-285.39%
FREE CASH FLOW
Cash From Operating Activities	$897.4M	$1.618B
Capital Expenditures	-$489.6M	-$269.6M
Free Cash Flow	$1.387B	$1.888B
YoY Change		-49.1%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001802768
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	us-gaap:AccountingStandardsUpdate201601Member
CY2019	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	us-gaap:AccountingStandardsUpdate201613Member
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-39329
CY2020	dei	Entity Registrant Name EntityRegistrantName	Royalty Pharma plc
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	X0
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1535773
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	110 East 59th Street
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10022
CY2020	dei	City Area Code CityAreaCode	212
CY2020	dei	Local Phone Number LocalPhoneNumber	883-0200
CY2020	dei	Security12b Title Security12bTitle	Class A ordinary shares, par value $0.0001
CY2020	dei	Trading Symbol TradingSymbol	RPRX
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	false
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	4200000000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1008680000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	246199000	USD
CY2020Q4	us-gaap	Trading Securities Debt TradingSecuritiesDebt	983279000	USD
CY2019Q4	us-gaap	Trading Securities Debt TradingSecuritiesDebt	94455000	USD
CY2020Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	587193000	USD
CY2019Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	452560000	USD
CY2020Q4	rprx	Accrued Royalty Receivable AccruedRoyaltyReceivable	33155000	USD
CY2019Q4	rprx	Accrued Royalty Receivable AccruedRoyaltyReceivable	33525000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	69984000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	0	USD
CY2020Q4	rprx	Other Royalty Income Receivable Current OtherRoyaltyIncomeReceivableCurrent	6011000	USD
CY2019Q4	rprx	Other Royalty Income Receivable Current OtherRoyaltyIncomeReceivableCurrent	5241000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	8596000	USD
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	92000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	2696898000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	832072000	USD
CY2020Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	12368084000	USD
CY2019Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	10842052000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	28666000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	51724000	USD
CY2020Q4	rprx	Equity Securities Fvni Noncurrent EquitySecuritiesFVNINoncurrent	298689000	USD
CY2019Q4	rprx	Equity Securities Fvni Noncurrent EquitySecuritiesFVNINoncurrent	380756000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	144416000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	131280000	USD
CY2020Q4	us-gaap	Derivative Assets Noncurrent DerivativeAssetsNoncurrent	5439000	USD
CY2019Q4	us-gaap	Derivative Assets Noncurrent DerivativeAssetsNoncurrent	42315000	USD
CY2020Q4	us-gaap	Equity Method Investments EquityMethodInvestments	454936000	USD
CY2019Q4	us-gaap	Equity Method Investments EquityMethodInvestments	124061000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	23158000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	45635000	USD
CY2020Q4	us-gaap	Assets Assets	16020286000	USD
CY2019Q4	us-gaap	Assets Assets	12449895000	USD
CY2020Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	126366000	USD
CY2019Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	31041000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	10775000	USD
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	11177000	USD
CY2020Q4	us-gaap	Interest Payable Current InterestPayableCurrent	42146000	USD
CY2019Q4	us-gaap	Interest Payable Current InterestPayableCurrent	0	USD
CY2020Q4	rprx	Accrued Purchase Obligation Current AccruedPurchaseObligationCurrent	110000000	USD
CY2019Q4	rprx	Accrued Purchase Obligation Current AccruedPurchaseObligationCurrent	0	USD
CY2020Q4	rprx	Milestone Payable Current MilestonePayableCurrent	18600000	USD
CY2019Q4	rprx	Milestone Payable Current MilestonePayableCurrent	0	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	281984000	USD
CY2020Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	USD
CY2019Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	9215000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	307887000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	333417000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	5816584000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	5956138000	USD
CY2020Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	USD
CY2019Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	18902000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	6124471000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	6308457000	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	rprx	Shareholders Contributions ShareholdersContributions	0	USD
CY2019Q4	rprx	Shareholders Contributions ShareholdersContributions	3282516000	USD
CY2019Q4	rprx	Deferred Shares Par Or Stated Value Per Share DeferredSharesParOrStatedValuePerShare	0.000001
CY2020Q4	rprx	Deferred Shares Par Or Stated Value Per Share DeferredSharesParOrStatedValuePerShare	0.000001
CY2020Q4	rprx	Deferred Shares Shares Issued DeferredSharesSharesIssued	316407000	shares
CY2020Q4	rprx	Deferred Shares Shares Outstanding DeferredSharesSharesOutstanding	316407000	shares
CY2019Q4	rprx	Deferred Shares Shares Issued DeferredSharesSharesIssued	0	shares
CY2019Q4	rprx	Deferred Shares Shares Outstanding DeferredSharesSharesOutstanding	0	shares
CY2020Q4	rprx	Deferred Shares Value Issued DeferredSharesValueIssued	0	USD
CY2019Q4	rprx	Deferred Shares Value Issued DeferredSharesValueIssued	0	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2865964000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	0	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1920635000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	2825212000	USD
CY2020Q4	us-gaap	Minority Interest MinorityInterest	5077036000	USD
CY2019Q4	us-gaap	Minority Interest MinorityInterest	35883000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	34395000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2093000	USD
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2317000	USD
CY2019Q4	us-gaap	Treasury Stock Value TreasuryStockValue	4266000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9895815000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6141438000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16020286000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12449895000	USD
CY2020	us-gaap	Revenues Revenues	2122353000	USD
CY2019	us-gaap	Revenues Revenues	1814254000	USD
CY2018	us-gaap	Revenues Revenues	1794894000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26289000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	83036000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	392609000	USD
CY2020	us-gaap	Provision For Loan And Lease Losses ProvisionForLoanAndLeaseLosses	230839000	USD
CY2019	us-gaap	Provision For Loan And Lease Losses ProvisionForLoanAndLeaseLosses	-1019321000	USD
CY2018	us-gaap	Provision For Loan And Lease Losses ProvisionForLoanAndLeaseLosses	-57334000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	23058000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	23924000	USD
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	33267000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	181715000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	103439000	USD
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	61906000	USD
CY2020	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	65053000	USD
CY2019	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	0	USD
CY2018	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	0	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	526954000	USD
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	-808922000	USD
CY2018	us-gaap	Costs And Expenses CostsAndExpenses	430448000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	1595399000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	2623176000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	1364446000	USD
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	44459000	USD
CY2019	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-32517000	USD
CY2018	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-7023000	USD
CY2020	us-gaap	Interest Expense InterestExpense	157059000	USD
CY2019	us-gaap	Interest Expense InterestExpense	268573000	USD
CY2018	us-gaap	Interest Expense InterestExpense	279956000	USD
CY2020	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	0	USD
CY2019	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	0	USD
CY2018	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	419481000	USD
CY2020	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-42076000	USD
CY2019	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-39138000	USD
CY2018	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	11923000	USD
CY2020	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	247073000	USD
CY2019	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	155749000	USD
CY2018	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-13939000	USD
CY2020	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	18600000	USD
CY2019	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	USD
CY2018	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	USD
CY2020	us-gaap	Investment Income Net InvestmentIncomeNet	28379000	USD
CY2019	us-gaap	Investment Income Net InvestmentIncomeNet	22329000	USD
CY2018	us-gaap	Investment Income Net InvestmentIncomeNet	24441000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-32821000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	393000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1518000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	106555000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-161757000	USD
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	153409000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1701954000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2461419000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1517855000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Profit Loss ProfitLoss	1701954000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	2461419000	USD
CY2018	us-gaap	Profit Loss ProfitLoss	1517855000	USD
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	726914000	USD
CY2019	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	112884000	USD
CY2018	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	140126000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	975040000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	2348535000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	1377729000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax	4066000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax	8003000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax	6189000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	83120000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	6159000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-402502000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	20551000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	USD
CY2018	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	66635000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	12348000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-394499000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	1041675000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	2360883000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	983230000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	12873000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1028802000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax	6189000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2360883000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	983230000	USD
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.32
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.32
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	375444000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	375455000	shares
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4460546000	USD
CY2018	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	1031823000	USD
CY2018	us-gaap	Profit Loss ProfitLoss	1517855000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-402502000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax	8003000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4552079000	USD
CY2019	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	880142000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	2461419000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	6159000	USD
CY2019	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	4266000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6141438000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6141438000	USD
CY2020	rprx	Noncontrolling Interest Increase From Contributions NoncontrollingInterestIncreaseFromContributions	1482322000	USD
CY2020	rprx	Noncontrolling Interest Transfers Of Interests NoncontrollingInterestTransfersOfInterests	0	USD
CY2020	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	1105765000	USD
CY2020	rprx	Stock Issued During Period Value Issued For Registration StockIssuedDuringPeriodValueIssuedForRegistration	63000	USD
	us-gaap	Profit Loss ProfitLoss	624885000	USD
CY2020	rprx	Stock Issued During Period Value Issued To Partnerships StockIssuedDuringPeriodValueIssuedToPartnerships	1000	USD
CY2020	rprx	Stockholders Equity Value Effect Of Exchange And Reallocation StockholdersEquityValueEffectOfExchangeAndReallocation	-1000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1908744000	USD
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5428000	USD
CY2020	us-gaap	Stockholders Equity Other StockholdersEquityOther	-191000	USD
CY2020	us-gaap	Dividends Cash DividendsCash	112490000	USD
	us-gaap	Profit Loss ProfitLoss	1077069000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax	4066000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	83120000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	20551000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9895815000	USD
CY2020	rprx	Proceeds From Cash Collections From Royalties Received On Financing Receivables ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables	2121923000	USD
CY2019	rprx	Proceeds From Cash Collections From Royalties Received On Financing Receivables ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables	1934092000	USD
CY2018	rprx	Proceeds From Cash Collections From Royalties Received On Financing Receivables ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables	2052592000	USD
CY2020	rprx	Proceeds From Cash Collections From Royalties Received On Intangible Assets ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets	143753000	USD
CY2019	rprx	Proceeds From Cash Collections From Royalties Received On Intangible Assets ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets	143298000	USD
CY2018	rprx	Proceeds From Cash Collections From Royalties Received On Intangible Assets ProceedsFromCashCollectionsFromRoyaltiesReceivedOnIntangibleAssets	106689000	USD
CY2020	rprx	Proceeds From Cash Collections From Other Royalties Received On Financing Receivables ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables	18305000	USD
CY2019	rprx	Proceeds From Cash Collections From Other Royalties Received On Financing Receivables ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables	27448000	USD
CY2018	rprx	Proceeds From Cash Collections From Other Royalties Received On Financing Receivables ProceedsFromCashCollectionsFromOtherRoyaltiesReceivedOnFinancingReceivables	125162000	USD
CY2020	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	42334000	USD
CY2019	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	14059000	USD
CY2018	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	39402000	USD
CY2020	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	7704000	USD
CY2019	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	20136000	USD
CY2018	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	24441000	USD
CY2020	rprx	Proceeds From Collateral Received On Derivative Instruments ProceedsFromCollateralReceivedOnDerivativeInstruments	45252000	USD
CY2019	rprx	Proceeds From Collateral Received On Derivative Instruments ProceedsFromCollateralReceivedOnDerivativeInstruments	360000	USD
CY2018	rprx	Proceeds From Collateral Received On Derivative Instruments ProceedsFromCollateralReceivedOnDerivativeInstruments	3467000	USD
CY2020	rprx	Payments For Collateral Posted On Derivative Instruments PaymentsForCollateralPostedOnDerivativeInstruments	0	USD
CY2019	rprx	Payments For Collateral Posted On Derivative Instruments PaymentsForCollateralPostedOnDerivativeInstruments	45630000	USD
CY2018	rprx	Payments For Collateral Posted On Derivative Instruments PaymentsForCollateralPostedOnDerivativeInstruments	510000	USD
CY2020	rprx	Payments To Terminate Derivative Instruments PaymentsToTerminateDerivativeInstruments	35448000	USD
CY2019	rprx	Payments To Terminate Derivative Instruments PaymentsToTerminateDerivativeInstruments	0	USD
CY2018	rprx	Payments To Terminate Derivative Instruments PaymentsToTerminateDerivativeInstruments	0	USD
CY2020	rprx	Payments For Ongoing Development Stage Funding PaymentsForOngoingDevelopmentStageFunding	20479000	USD
CY2019	rprx	Payments For Ongoing Development Stage Funding PaymentsForOngoingDevelopmentStageFunding	83036000	USD
CY2018	rprx	Payments For Ongoing Development Stage Funding PaymentsForOngoingDevelopmentStageFunding	108163000	USD
CY2020	rprx	Payments For Upfront Development Stage Funding PaymentsForUpfrontDevelopmentStageFunding	5810000	USD
CY2019	rprx	Payments For Upfront Development Stage Funding PaymentsForUpfrontDevelopmentStageFunding	0	USD
CY2018	rprx	Payments For Upfront Development Stage Funding PaymentsForUpfrontDevelopmentStageFunding	284446000	USD
CY2020	rprx	Payments For Operating Costs And Professional Services PaymentsForOperatingCostsAndProfessionalServices	179709000	USD
CY2019	rprx	Payments For Operating Costs And Professional Services PaymentsForOperatingCostsAndProfessionalServices	88524000	USD
CY2018	rprx	Payments For Operating Costs And Professional Services PaymentsForOperatingCostsAndProfessionalServices	72535000	USD
CY2020	rprx	Payments For Rebates PaymentsForRebates	0	USD
CY2019	rprx	Payments For Rebates PaymentsForRebates	0	USD
CY2018	rprx	Payments For Rebates PaymentsForRebates	125000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	103196000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	254964000	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	267657000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2034629000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1667239000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1618317000	USD
CY2020	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	15084000	USD
CY2019	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	0	USD
CY2018	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	0	USD
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	USD
CY2019	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	125121000	USD
CY2018	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	USD
CY2020	rprx	Payments To Acquire Warrants PaymentsToAcquireWarrants	0	USD
CY2019	rprx	Payments To Acquire Warrants PaymentsToAcquireWarrants	8840000	USD
CY2018	rprx	Payments To Acquire Warrants PaymentsToAcquireWarrants	0	USD
CY2020	rprx	Payments To Acquire Equity Securities Fnni PaymentsToAcquireEquitySecuritiesFNNI	50000000	USD
CY2019	rprx	Payments To Acquire Equity Securities Fnni PaymentsToAcquireEquitySecuritiesFNNI	78999000	USD
CY2018	rprx	Payments To Acquire Equity Securities Fnni PaymentsToAcquireEquitySecuritiesFNNI	152810000	USD
CY2020	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	3000000	USD
CY2019	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	150000000	USD
CY2018	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	750000000	USD
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1705283000	USD
CY2019	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	817402000	USD
CY2018	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	815440000	USD
CY2019	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	725070000	USD
CY2018	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
CY2020	rprx	Proceeds From Issuance Of Equity Securities Fnni ProceedsFromIssuanceOfEquitySecuritiesFNNI	384840000	USD
CY2019	rprx	Proceeds From Issuance Of Equity Securities Fnni ProceedsFromIssuanceOfEquitySecuritiesFNNI	0	USD
CY2018	rprx	Proceeds From Issuance Of Equity Securities Fnni ProceedsFromIssuanceOfEquitySecuritiesFNNI	0	USD
CY2020	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	40155000	USD
CY2019	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	27042000	USD
CY2018	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	24173000	USD
CY2020	us-gaap	Payments To Acquire Finance Receivables PaymentsToAcquireFinanceReceivables	2182246000	USD
CY2019	us-gaap	Payments To Acquire Finance Receivables PaymentsToAcquireFinanceReceivables	1721291000	USD
CY2018	us-gaap	Payments To Acquire Finance Receivables PaymentsToAcquireFinanceReceivables	269593000	USD
CY2020	rprx	Payments For Milestones PaymentsForMilestones	0	USD
CY2019	rprx	Payments For Milestones PaymentsForMilestones	250000000	USD
CY2018	rprx	Payments For Milestones PaymentsForMilestones	0	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2759320000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2153625000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	303424000	USD
CY2020	rprx	Payments For Distributions To Shareholders And Unitholders PaymentsForDistributionsToShareholdersAndUnitholders	285353000	USD
CY2019	rprx	Payments For Distributions To Shareholders And Unitholders PaymentsForDistributionsToShareholdersAndUnitholders	739276000	USD
CY2018	rprx	Payments For Distributions To Shareholders And Unitholders PaymentsForDistributionsToShareholdersAndUnitholders	814359000	USD
CY2020	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	543952000	USD
CY2019	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	154084000	USD
CY2018	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	268693000	USD
CY2020	rprx	Payments To Noncontrolling Interests Other PaymentsToNoncontrollingInterestsOther	181135000	USD
CY2019	rprx	Payments To Noncontrolling Interests Other PaymentsToNoncontrollingInterestsOther	0	USD
CY2018	rprx	Payments To Noncontrolling Interests Other PaymentsToNoncontrollingInterestsOther	0	USD
CY2020	rprx	Payment Of Dividends To Shareholders PaymentOfDividendsToShareholders	112490000	USD
CY2019	rprx	Payment Of Dividends To Shareholders PaymentOfDividendsToShareholders	0	USD
CY2018	rprx	Payment Of Dividends To Shareholders PaymentOfDividendsToShareholders	0	USD
CY2020	rprx	Proceeds From Noncontrolling Interests Research And Development ProceedsFromNoncontrollingInterestsResearchAndDevelopment	8482000	USD
CY2019	rprx	Proceeds From Noncontrolling Interests Research And Development ProceedsFromNoncontrollingInterestsResearchAndDevelopment	0	USD
CY2018	rprx	Proceeds From Noncontrolling Interests Research And Development ProceedsFromNoncontrollingInterestsResearchAndDevelopment	0	USD
CY2020	rprx	Proceeds From Noncontrolling Interests Other ProceedsFromNoncontrollingInterestsOther	58957000	USD
CY2019	rprx	Proceeds From Noncontrolling Interests Other ProceedsFromNoncontrollingInterestsOther	0	USD
CY2018	rprx	Proceeds From Noncontrolling Interests Other ProceedsFromNoncontrollingInterestsOther	0	USD
CY2020	rprx	Repayments Of Long Term Debt Scheduled Payments RepaymentsOfLongTermDebtScheduledPayments	94200000	USD
CY2019	rprx	Repayments Of Long Term Debt Scheduled Payments RepaymentsOfLongTermDebtScheduledPayments	294000000	USD
CY2018	rprx	Repayments Of Long Term Debt Scheduled Payments RepaymentsOfLongTermDebtScheduledPayments	294000000	USD
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	11116196000	USD
CY2019	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2018	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	11891030000	USD
CY2019	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2018	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	46715000	USD
CY2019	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2018	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	2049000	USD
CY2020	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2019	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	4266000	USD
CY2018	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	1908744000	USD
CY2019	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2018	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1487172000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1191626000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1379101000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	762481000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1678012000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	542640000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	246199000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1924211000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1381571000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1008680000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	246199000	USD
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1924211000	USD
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of income, revenues and expenses during the reporting period. Actual results may differ from those estimates.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The precise extent to which the COVID-19 pandemic will impact our operational and financial performance will depend on various factors. To date, the pandemic has not materially impacted our financial performance and we do not believe it is reasonably likely to in the future. Due to the nature of our business, the effect of the COVID-19 pandemic may not be fully reflected in certain of our results of operations until future periods.</span></div>
CY2020Q2	rprx	Number Of Noncontrolling Interests Created NumberOfNoncontrollingInterestsCreated	2	partnership
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, financial royalty assets and receivables. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds are needed for operations. Our cash and cash equivalents and marketable securities balances at December 31, 2020 and 2019 were held with State Street, Deutsche Bank and Bank of America. Our primary operating accounts significantly exceed the FDIC limits.The majority of our financial royalty assets and receivables arise from contractual royalty agreements that entitle us to royalties on the sales of underlying biopharmaceutical products in the United States, Europe and the rest of the world, with concentrations of credit risk limited due to the broad range of marketers responsible for paying royalties to us and the variety of geographies from which our royalties on product sales are derived. The products in which we hold royalties are marketed by leading industry participants, including, among others, Abbott, AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Gilead, Johnson & Johnson, Lilly, Merck, Pfizer, Novartis, Biogen, Roche/ Genentech and Vertex.
CY2020	us-gaap	Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss	-45200000	USD
CY2019	us-gaap	Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss	125600000	USD
CY2018	us-gaap	Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss	-7800000	USD
CY2020	rprx	Payments To Terminate Derivative Instruments PaymentsToTerminateDerivativeInstruments	35400000	USD
CY2020	rprx	Proceeds From Collateral Received On Derivative Instruments ProceedsFromCollateralReceivedOnDerivativeInstruments	45300000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	45600000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	125121000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	89279000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	214400000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	125121000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	6159000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	131280000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	70000000.0	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	144400000	USD
CY2020Q4	us-gaap	Notes Receivable Gross NotesReceivableGross	14219101000	USD
CY2020Q4	rprx	Financing Receivable Allowance For Credit Loss Changes In Expected Cash Flows FinancingReceivableAllowanceForCreditLossChangesInExpectedCashFlows	940107000	USD
CY2020Q4	rprx	Financing Receivables After Allowance For Credit Loss Changes In Expected Cash Flows FinancingReceivablesAfterAllowanceForCreditLossChangesInExpectedCashFlows	13278994000	USD
CY2020Q4	rprx	Financing Receivable Allowance For Credit Loss Cumulative Adjustment And Credit Loss Expense Reversal FinancingReceivableAllowanceForCreditLossCumulativeAdjustmentAndCreditLossExpenseReversal	323717000	USD
CY2020Q4	us-gaap	Notes Receivable Net NotesReceivableNet	12955277000	USD
CY2019Q4	us-gaap	Notes Receivable Gross NotesReceivableGross	12163030000	USD
CY2019Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	868418000	USD
CY2019Q4	us-gaap	Notes Receivable Net NotesReceivableNet	11294612000	USD
CY2017Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	2045868000	USD
CY2018	rprx	Financing Receivable Change In Present Value Increases To Cumulative Allowance Expense FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense	284214000	USD
CY2018	rprx	Financing Receivable Change In Present Value Decreases To Cumulative Allowance Reversal Of Expense FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense	341548000	USD
CY2018	us-gaap	Financing Receivable Change In Present Value Expense Reversal FinancingReceivableChangeInPresentValueExpenseReversal	-5637000	USD
CY2018Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	1982897000	USD
CY2019	rprx	Financing Receivable Change In Present Value Increases To Cumulative Allowance Expense FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense	322717000	USD
CY2019	rprx	Financing Receivable Change In Present Value Decreases To Cumulative Allowance Reversal Of Expense FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense	1342038000	USD
CY2019	us-gaap	Financing Receivable Change In Present Value Expense Reversal FinancingReceivableChangeInPresentValueExpenseReversal	-95158000	USD
CY2019Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	868418000	USD
CY2020	rprx	Financing Receivable Change In Present Value Increases To Cumulative Allowance Expense FinancingReceivableChangeInPresentValueIncreasesToCumulativeAllowanceExpense	645612000	USD
CY2020	rprx	Financing Receivable Change In Present Value Decreases To Cumulative Allowance Reversal Of Expense FinancingReceivableChangeInPresentValueDecreasesToCumulativeAllowanceReversalOfExpense	570959000	USD
CY2020	us-gaap	Financing Receivable Change In Present Value Expense Reversal FinancingReceivableChangeInPresentValueExpenseReversal	-2964000	USD
CY2020	us-gaap	Financing Receivable Allowance For Credit Losses Write Offs FinancingReceivableAllowanceForCreditLossesWriteOffs	25174000	USD
CY2020	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	156186000	USD
CY2020Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	1263824000	USD
CY2020	rprx	Financing Receivable Allowance For Credit Loss Financial Royalty Asset Writeoff FinancingReceivableAllowanceForCreditLossFinancialRoyaltyAssetWriteoff	90200000	USD
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	375444000	shares
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	606216000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	577550000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	28666000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	606216000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	554492000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	51724000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26300000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	83000000.0	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	392600000	USD
CY2020	rprx	Net Income Loss Attributable To Parent Prior To Offering NetIncomeLossAttributableToParentPriorToOffering	479842000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	495198000	USD
CY2020Q4	rprx	Number Of Noncontrolling Interests NumberOfNoncontrollingInterests	4	noncontrolling_interest
CY2020	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	112500000	USD
CY2020	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.15
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5700000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	1701954000	USD
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.32
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	495198000	USD
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	375444000	shares
CY2020	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	11000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	375455000	shares
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.32
CY2020	us-gaap	Profit Loss ProfitLoss	1701954000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	2461419000	USD
CY2018	us-gaap	Profit Loss ProfitLoss	1517855000	USD
CY2020	us-gaap	Provision For Loan And Lease Losses ProvisionForLoanAndLeaseLosses	230839000	USD
CY2019	us-gaap	Provision For Loan And Lease Losses ProvisionForLoanAndLeaseLosses	-1019321000	USD
CY2018	us-gaap	Provision For Loan And Lease Losses ProvisionForLoanAndLeaseLosses	-57334000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	23058000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	23924000	USD
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	33267000	USD
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	11715000	USD
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	12790000	USD
CY2018	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	13127000	USD
CY2020	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	0	USD
CY2019	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	0	USD
CY2018	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	419481000	USD
CY2020	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-42076000	USD
CY2019	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-39138000	USD
CY2018	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	11923000	USD
CY2020	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	247073000	USD
CY2019	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	155749000	USD
CY2018	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-13939000	USD
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	44459000	USD
CY2019	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-32517000	USD
CY2018	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-7023000	USD
CY2020	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	42334000	USD
CY2018	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2019	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	14059000	USD
CY2018	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	39402000	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-30272000	USD
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2018	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	5428000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	0	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	0	USD
CY2020	rprx	Investment Income Net Reclassification Of Available For Sale Debt Securities Gain Loss InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss	20551000	USD
CY2019	rprx	Investment Income Net Reclassification Of Available For Sale Debt Securities Gain Loss InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss	0	USD
CY2018	rprx	Investment Income Net Reclassification Of Available For Sale Debt Securities Gain Loss InvestmentIncomeNetReclassificationOfAvailableForSaleDebtSecuritiesGainLoss	0	USD
CY2020	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	18600000	USD
CY2019	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	USD
CY2018	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	USD
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	65053000	USD
CY2019	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2020	rprx	Gain Loss On Derivative Financial Instruments GainLossOnDerivativeFinancialInstruments	34952000	USD
CY2019	rprx	Gain Loss On Derivative Financial Instruments GainLossOnDerivativeFinancialInstruments	0	USD
CY2018	rprx	Gain Loss On Derivative Financial Instruments GainLossOnDerivativeFinancialInstruments	0	USD
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-9621000	USD
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	2122000	USD
CY2018	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	7771000	USD
CY2020	us-gaap	Increase Decrease In Finance Receivables IncreaseDecreaseInFinanceReceivables	1959975000	USD
CY2019	us-gaap	Increase Decrease In Finance Receivables IncreaseDecreaseInFinanceReceivables	1648837000	USD
CY2018	us-gaap	Increase Decrease In Finance Receivables IncreaseDecreaseInFinanceReceivables	1524816000	USD
CY2020	rprx	Increase Decrease In Cash Collections On Financing Receivables IncreaseDecreaseInCashCollectionsOnFinancingReceivables	2121923000	USD
CY2019	rprx	Increase Decrease In Cash Collections On Financing Receivables IncreaseDecreaseInCashCollectionsOnFinancingReceivables	1934092000	USD
CY2018	rprx	Increase Decrease In Cash Collections On Financing Receivables IncreaseDecreaseInCashCollectionsOnFinancingReceivables	2052592000	USD
CY2020	rprx	Increase Decrease In Debt Securities Available For Sale IncreaseDecreaseInDebtSecuritiesAvailableForSale	0	USD
CY2019	rprx	Increase Decrease In Debt Securities Available For Sale IncreaseDecreaseInDebtSecuritiesAvailableForSale	150000000	USD
CY2018	rprx	Increase Decrease In Debt Securities Available For Sale IncreaseDecreaseInDebtSecuritiesAvailableForSale	150000000	USD
CY2020	rprx	Increase Decrease In Accrued Royalty Receivable IncreaseDecreaseInAccruedRoyaltyReceivable	-370000	USD
CY2019	rprx	Increase Decrease In Accrued Royalty Receivable IncreaseDecreaseInAccruedRoyaltyReceivable	-2471000	USD
CY2018	rprx	Increase Decrease In Accrued Royalty Receivable IncreaseDecreaseInAccruedRoyaltyReceivable	27372000	USD
CY2020	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	0	USD
CY2019	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-150000000	USD
CY2018	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-150000000	USD
CY2020	rprx	Increase Decrease In Other Royalty Income Receivable IncreaseDecreaseInOtherRoyaltyIncomeReceivable	770000	USD
CY2019	rprx	Increase Decrease In Other Royalty Income Receivable IncreaseDecreaseInOtherRoyaltyIncomeReceivable	-7390000	USD
CY2019	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-4607000	USD
CY2018	rprx	Increase Decrease In Other Royalty Income Receivable IncreaseDecreaseInOtherRoyaltyIncomeReceivable	11099000	USD
CY2020	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	10278000	USD
CY2018	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	442000	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-45264000	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	45635000	USD
CY2018	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-766000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	6496000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1350000	USD
CY2020	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	42146000	USD
CY2019	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	USD
CY2018	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2034629000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1667239000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1618317000	USD
CY2020	us-gaap	Transfer Of Investments TransferOfInvestments	303679000	USD
CY2019	us-gaap	Transfer Of Investments TransferOfInvestments	0	USD
CY2018	us-gaap	Transfer Of Investments TransferOfInvestments	0	USD
CY2020	rprx	Settlements With Equity Method Investments SettlementsWithEquityMethodInvestments	5700000	USD
CY2019	rprx	Settlements With Equity Method Investments SettlementsWithEquityMethodInvestments	0	USD
CY2018	rprx	Settlements With Equity Method Investments SettlementsWithEquityMethodInvestments	0	USD
CY2020	rprx	Accrued Purchase Obligation Equity Investment AccruedPurchaseObligationEquityInvestment	110000000	USD
CY2019	rprx	Accrued Purchase Obligation Equity Investment AccruedPurchaseObligationEquityInvestment	0	USD
CY2018	rprx	Accrued Purchase Obligation Equity Investment AccruedPurchaseObligationEquityInvestment	0	USD
CY2020	rprx	Repayments Of Long Term Debt Contributions From Noncontrolling Interest Noncash RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash	1103774000	USD
CY2019	rprx	Repayments Of Long Term Debt Contributions From Noncontrolling Interest Noncash RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash	0	USD
CY2018	rprx	Repayments Of Long Term Debt Contributions From Noncontrolling Interest Noncash RepaymentsOfLongTermDebtContributionsFromNoncontrollingInterestNoncash	0	USD
CY2020	rprx	Milestone Payment Accrued But Not Paid MilestonePaymentAccruedButNotPaid	18600000	USD
CY2019	rprx	Milestone Payment Accrued But Not Paid MilestonePaymentAccruedButNotPaid	0	USD
CY2018	rprx	Milestone Payment Accrued But Not Paid MilestonePaymentAccruedButNotPaid	0	USD
CY2018	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-402502000	USD
CY2018	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	8003000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	6159000	USD
CY2019	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	6189000	USD
CY2020	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	-6855000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	60617000	USD
CY2020	rprx	Other Comprehensive Income Loss Reclassification Adjustment Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossReclassificationAdjustmentAttributableToNoncontrollingInterest	24022000	USD
CY2020Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	126400000	USD
CY2019Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	31000000.0	USD
CY2018Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	44300000	USD

Files In Submission

Name	View Source	Status
0001802768-21-000006-index-headers.html	Edgar Link	pending
0001802768-21-000006-index.html	Edgar Link	pending
0001802768-21-000006.txt	Edgar Link	pending
0001802768-21-000006-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
rprx-20201231.htm	Edgar Link	pending
rprx-20201231.xsd	Edgar Link	pending
rprx-20201231ex231.htm	Edgar Link	pending
rprx-20201231ex311.htm	Edgar Link	pending
rprx-20201231ex312.htm	Edgar Link	pending
rprx-20201231ex32.htm	Edgar Link	pending
rprx-20201231ex42.htm	Edgar Link	pending
rprx-20201231_cal.xml	Edgar Link	unprocessable
rprx-20201231_def.xml	Edgar Link	unprocessable
rprx-20201231_g1.jpg	Edgar Link	pending
rprx-20201231_g2.jpg	Edgar Link	pending
rprx-20201231_g3.jpg	Edgar Link	pending
rprx-20201231_g4.jpg	Edgar Link	pending
rprx-20201231_htm.xml	Edgar Link	completed
rprx-20201231_lab.xml	Edgar Link	unprocessable
rprx-20201231_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RPRX
Royalty Pharma plc Stock $rprx

2019 Q4 Form 10-K Financial Statement

#000180276821000006 Filed on February 24, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RPRX Royalty Pharma plc Stock $rprx

2019 Q4 Form 10-K Financial Statement

#000180276821000006 Filed on February 24, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RPRX
Royalty Pharma plc Stock $rprx